Recombinant human granulocyte-macrophage colony-stimulating factor accelerates engraftment kinetics after allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia

Haematologica

Volumn 84, Issue 2, 1999, Pages 133-137

  Madero, Luis ^a   Díaz, Miguel Angel ^a   Ortega, Juan José ^b   Olive, Teresa ^b   Martínez, Ana ^c   Badell, Isabel ^d   Muñoz, Arturo ^e   Gómez, Pedro ^f  

^a HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^e HOSPITAL RAMÓN Y CAJAL   (Spain)

^f HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

ALL; Allogeneic bone marrow transplanta; Childhood; RhGM CSF; Tion

Indexed keywords

ANTINEOPLASTIC AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETOPOSIDE; HLA ANTIGEN; MELPHALAN; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BLOOD CELL COUNT; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GRAFT VERSUS HOST REACTION; HOSPITALIZATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; RELAPSE; SURVIVAL;

ADOLESCENT; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; FEMALE; GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTORS, RECOMBINANT; HUMANS; KINETICS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; MALE; PROSPECTIVE STUDIES; TRANSPLANTATION, HOMOLOGOUS;

EID: 0344172179     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Sanders JE, Thomas ED, Buckner CD, et al. Marrow transplantation in children with acute lymphoblastic leukemia in second remission. Blood 1987; 70:324-6.
2. Dopier R, Henze G, Bender-Coetze C, et al. Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission after intensive primary and relapse therapy according to the BFM and Co ALL protocols: results of the German Cooperative Study. Blood 1991; 78:2780-4.
3. Zikos P, Van Lint MT, Lamparelli T, et al. Allogeneic hemopoietic stem cell transplantation for patients with high risk acute lymphoblastic leukemia: favorable impact of chronic graft-versus-host disease on survival and relapse. Haematologica 1998; 83:896-903.
4. Wingard JR. Prevention and treatment of bacterial and fungal infections. In: Forman SJ, Blume GG, Thomas ED, eds. Bone Marrow Transplantation. Boston: Blackwell Scientific Publ., 1994. p. 363-75.
5. Wingard JR. Advances in the management of infectious complications after bone marrow transplantation. Bone Marrow Transplant 1990; 6:377-83.
6. Visani G, Gamberi B, Greenberg P, et al. The use of GM-CSF as an adjunct to autologous/ syngeneic bone marrow transplantation: a prospective randomized controlled trial. Bone Marrow Transplant 1991; 7: (Suppl 2)81-2.
7. Link H, Boogaerts M, Carella A, et al. A controlled trial of recombinant human granulocyte-macrophage colony-stimulating factors after total body irradiation, high-dose chemotherapy and autologous bone marrow transplantation for acute lymphoblastic leukemia or malignant lymphoma. Blood 1992; 80:2188-95.
8. Greenberg P, Advani R, Keating A, et al. GM-CSF accelerates neutrophil recovery after autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 1996; 18:1057-64.
9. Nemunaitis J, Buckner CD, Applebaunn FR, et al. Phase I/II trial of recombinant human granulocyte-macrophage colony stimulating factor following allogeneic bone marrow transplantation. Blood 1991; 77:2065-71.
10. Nemunaitis J, Anasetti G, Storb R, et al. Phase II trial of recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) in patients undergoing allogeneic bone marrow transplantation from unrelated donors. Blood 1992; 79:2572-7.
11. De Witte T, Gratwhol A, Van der Lely N, et al. Recombinant human granulocyte-macrophage colony-stimulating factor accelerates neutrophil and monocyte recovery after allogeneic T-cell depleted bone marrow transplantation. Blood 1992; 79: 1359-65.
12. Nemunaitis J, Anassetti C, Buckner CD, et al. Long-term follow-up of 103 patients who received rhGM-CSF after unrelated donor bone marrow transplant. Blood 1992; 81:865-71.
13. Nemunaitis J, Rosenfeld CS, Ash R, et al. Phase III randomized double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation. Bone Marrow Transplant 1995; 15: 949-54.
14. Singhal S, Powles R, Treleaven J, et al. Long-term safety of GM-CSF (molgrasnostin) administration after bone marrow transplantation for malignancies: follow-up of a double blind randomized placebo study. Leuk Lymphoma 1997; 24:301-7.
15. Clift RA, Buckner CD, Thomas ED, et al. Allogeneic bone marrow transplantation using fractionated total body irradiation in patients with acute lymphoblastic leukemia in relapse. Leukemia Res 1982; 6:401-7.
16. Shank B, Chu FCH, Dinsmore R, et al. Hyperfractionated total body irradiation for bone marrow transplantation. Int J Radiat Oncol Biol Phys 1981; 7:1109-15.
17. Tutschka PJ, Copeland EA, Klein JP. Bone marrow transplantation for leukemia following a new busulphan and cyclophosphamide regimen. Blood 1987; 70:1382-8.
18. Emminger W, Emminger-Schmindmeier W, Haas OA, et al. Treatment of infant leukemia with busulphan, cyclophosphamide, etoposide and bone marrow transplantation. Bone Marrow Transplant 1992; 9:313-8.
19. Martino R, Badell I, Brunet S, et al. High-dose busulphan and melphalan before bone marrow for acute non-lymphoblastic leukemia. Bone Marrow Transplant 1995; 16:209-12.
20. Spitzer TR, Cottler-Fox M, Torrisi J, et al. Escalating dose of etoposide with cyclophosphamide and fractionated total body irradiation or busulphan as conditioning for bone marrow transplantation. Bone Marrow Transplant 1989; 4:559-65.
21. Storb R, Deeg HJ, Pepe M, et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of controlled trial. Blood 1989; 73:1729-33.
22. Thomas ED, Storb R, Clift RA. Bone marrow transplantation. N Engl J Med 1975; 292:891-5.
23. Bearman SI, Appelbaum FR, Buckner CD, et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6:1562-8.
24. Nemunaitis J, Buckner CD, Applebaum FR, et al. Phase I/II trial of recombinant human granulocyte-macrophage colony-stimulating factor following allogeneic bone marrow transplantation. Blood 1991; 77:2065-71.
25. Martin-Algarre S, Bishop MR, Tarantolo S. Hematopoietic growth factors after HLA identical allogeneic bone marrow transplantation in patients treated with methotrexate containing graft-vs-host disease prophylaxis. Exp Hematol 1995; 23:1503-8.
26. Gulati SC, Bennett CL. Granulocyte-macrophage colony-stimulating factor (GM-CSF) as adjuvant therapy in relapsed Hodgkin's disease. Ann Intern Med 1992; 116:177-81.
27. Zauli G, Vitale L, Brunnelli MA, et al. Prevalence of the primitive megakaryocyte progenitors (BFU-Meg) in adult human peripheral blood. Exp Hematol 1992; 20:850-4.
28. Schmitz N, Bacigalupo A, Hasenclever D, et al. Allogeneic bone marrow transplantation vs filgrastimmobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomized multicentre trial of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1998; 21:995-1003.
29. Madero L, Muñoz A, Díaz de Heredia A, et al. G-CSF after autologous bone marrow transplantation for malignant diseases in children. Bone Marrow Transplant 1995; 15:349-51.